Clinical practice guidelines for hepatocellular carcinoma differ between Japan, United States, and Europe

Liver Cancer

Volumn 4, Issue 2, 2015, Pages 85-95

  Kudo, M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALGORITHM; CANCER PATIENT; COMPUTER ASSISTED TOMOGRAPHY; EUROPE; EVIDENCE BASED MEDICINE; HUMAN; JAPAN; LIVER CELL CARCINOMA; LIVER NODULE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; TREATMENT INDICATION; UNITED STATES;

EID: 85032642934     PISSN: 22351795     EISSN: 16645553     Source Type: Journal    
DOI: 10.1159/000367730     Document Type: Review

References (25)

1. Bruix J, Sherman M, American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma: An update. Hepatology 2011;53:1020-1022.
2. European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer: EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908-943.
3. Group formed to establish "Guidelines for evidence-based clinical practice for the treatment of liver cancer." Clinical practice guidelines for hepatocellular carcinoma. Tokyo, Kanehara, 2005 (in Japanese).
4. Makuuchi M, Kokudo N, Arii S, Futagawa S, Kaneko S, Kawasaki S, Matsuyama Y, Okazaki M, Okita K, Omata M, Saida Y, Takayama T, Yamaoka Y: Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res 2008;38:37-51.
5. Japan Society of Hepatology: Clinical practice guidelines for hepatocellular carcinoma (2013 version). Kanehara, Tokyo, Japan 2013.
6. Kokudo N, Hasegawa K, Akahane M, Igaki H, Izumi N, Ichida T, Uemoto S, Kaneko S, Kawasaki S, Ku Y, Kudo M, Kubo S, Takayama T, Tateishi R, Fukuda T, Matsui O, Matsuyama Y, Murakami T, Arii S, Okazaki M, Makuuchi M: Evidence-based clinical practice guidelines for hepatocellular carcinoma: the Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines). Hepatol Res 2015 (in press).
7. Japan Society of Hepatology: Management of Hepatocellular Carcinoma in Japan: Consensus-based Clinical Practice Manual, second edition, Igaku-Shoin, Tokyo, 2010 (in Japanese).
8. Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima O, Kojiro M, Makuuchi M, HCC Expert Panel of Japan Society of Hepatology: Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis 2011;29:339-364.
9. Kudo M: Alpha-fetoprotein-L3: useful or useless for hepatocellular carcinoma? Liver Cancer 2013;2:151-152.
10. Song P, Gao J, Inagaki Y, Kokudo N, Hasegawa K, Sugawara Y, Tang W: Biomarkers: evaluation of screening for and early diagnosis of hepatocellular carcinoma in Japan and China. Liver Cancer 2013;2:31-39.
11. Ichikawa T, Sano K, Morisaka H: Diagnosis of pathologically early HCC with EOB-MRI: experiences and current consensus. Liver Cancer 2014;3:97-107.
12. Mise Y, Sakamoto Y, Ishizawa T, Kaneko J, Aoki T, Hasegawa K, Sugawara Y, Kokudo N: A worldwide survey of the current daily practice in liver surgery. Liver Cancer 2013;2:55-66.
13. Lin SM: Local ablation for hepatocellular carcinoma in Taiwan. Liver Cancer 2013;2:73-83.
14. Chan SC: Liver transplantation for hepatocellular carcinoma. Liver Cancer 2013;2:338-344.
15. Raoul JL, Gilabert M, Piana G: How to define transarterial chemoembolization failure or refractoriness: A European perspective. Liver Cancer 2014;3:119-124.
16. Kudo M: Biomarkers and personalized sorafenib therapy. Liver Cancer 2014;3:399-404.
17. Kudo M: Treatment of advanced hepatocellular carcinoma with emphasis on hepatic arterial infusion chemotherapy and molecular targeted therapy. Liver Cancer 2012;1:62-70.
18. Kudo M: Early hepatocellular carcinoma: definition and diagnosis. Liver Cancer 2013;2:69-72.
19. Kudo M, Matsui O, Izumi N, Iijima H, Kadoya M, Imai Y, Okusaka T, Miyayama S, Tsuchiya K, Ueshima K, Hiraoka A, Ikeda M, Ogasawara S, Yamashita T, Minami T, Yamakado K, Liver Cancer Study Group of Japan: JSH Consensus-based Clinical Practice Guideline for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan. Liver Cancer 2014;3:458-468.
20. Kim YK, Kim CS, Chung GH, Han YM, Lee SY, Jin GY, Lee JM: Radiofrequency ablation of hepatocellular carcinoma in patients with decompensated cirrhosis: evaluation of therapeutic efficacy and safety. AJR Am J Roentgenol 2006;186(Suppl):S261-S268.
21. Kudo M, Osaki Y, Matsunaga T, Kasugai H, Oka H, Seki T: Hepatocellular carcinoma in Child-Pugh C cirrhosis: prognostic factors and survival benefit of nontransplant treatments. Dig Dis 2013;31:490-498.
22. Nishikawa H, Kita R, Kimura T, Ohara Y, Takeda H, Sakamoto A, Saito S, Nishijima N, Nasu A, Komekado H, Osaki Y: Clinical efficacy of non-transplant therapies in patients with hepatocellular carcinoma with Child-Pugh C liver cirrhosis. Anticancer Res 2014;34:3039-3044.
23. Wakuta A, Nouso K, Kariyama K, Nishimura M, Kishida M, Wada N, Mizushima T, Higashi T, Tanimoto M: Radiofrequency ablation for the treatment of hepatocellular carcinoma with decompensated cirrhosis. Oncology 2011;81:39-44.
24. Nouso K, Ito Y, Kuwaki K, Kobayashi Y, Nakamura S, Ohashi Y, Yamamoto K: Prognostic factors and treatment effects for hepatocellular carcinoma in Child C cirrhosis. Br J Cancer 2008;98:1161-1165.
25. Nouso K, Kokudo N, Tanaka M, Kuromatsu R, Nishikawa H, Toyoda H, Oishi N, Kuwaki K, Kusanaga M, Sakaguchi T, Morise Z, Kitai S, Kudo M: Treatment of hepatocellular carcinoma with Child-Pugh C cirrhosis. Oncology 2014;87(Suppl 1):99-103.